China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General Manager (GM), Pascal Qian, to the position of Chief Commercial Officer (COO). This strategic move comes as LianBio prepares for the potential market launch of mavacamten, a first-in-class molecule for the treatment of obstructive hypertrophic cardiomyopathy (HCM), which has been filed for approval in China with priority review status and is expected to reach the market by 2024.
Pascal Qian’s Industry Experience and Background
Pascal Qian brings extensive industry experience to his new role, having previously led Eli Lilly & Co’s (NYSE: LLY) China oncology business unit and served as Novartis’s executive director of the solid tumors business unit in China. He also held various positions at Pfizer before joining LianBio in July 2021. Qian’s deep knowledge of the pharmaceutical industry and proven leadership skills position him well to oversee LianBio’s commercial operations as the company anticipates the potential launch of mavacamten.
Mavacamten’s Potential Impact on the Market
Mavacamten’s priority review status in China highlights the drug’s potential significance in addressing the unmet medical needs of patients with obstructive HCM. As LianBio moves closer to bringing this innovative treatment to market, the appointment of Pascal Qian as COO underscores the company’s commitment to building a strong commercial foundation to support the successful launch and market penetration of mavacamten.-Fineline Info & Tech
